IDEAYA Reports Q2 2026 Results: $1.24B Cash, Darovasertib NDA Underway, Multiple ESMO Data Updates Planned
IDYA sits 60% above its 52-week low of $22.09 on light trading volume (0.4× avg).
Summary
IDEAYA Biosciences reported Q2 2026 financial results with $1.24 billion in cash and a net loss of $112.5 million. The company is advancing its darovasertib NDA under real-time review and plans multiple data readouts at ESMO, including for its DLL3 ADC and neoadjuvant uveal melanoma programs.
Key Events · Earnings and Guidance · IDYA
-
Darovasertib NDA Under Real-Time Review
NDA filing for darovasertib in metastatic uveal melanoma is underway under the FDA's RTOR program, with completion expected in H2 2026. The registrational OptimUM-02 trial met its primary endpoint with a median PFS of 6.9 months vs 3.1 months for investigator's choice.
-
Multiple ESMO Data Catalysts
Updated data from the OptimUM-01 trial in HLA*A2-positive mUM, the OptimUM-09 neoadjuvant trial, and the Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 ADC) in SCLC/NEC will be presented at ESMO in October 2026.
-
Strong Cash Position, Runway to 2030
Cash, cash equivalents, and marketable securities totaled $1.24 billion as of June 30, 2026, following a $323.4 million public offering and $33.1 million in ATM sales. Cash runway guidance into 2030 is unchanged.
-
Q2 2026 Financials: Widening Loss
Net loss for Q2 2026 was $112.5 million, up from $98.5 million in Q1 2026, driven by higher R&D expenses ($108.7M) and G&A ($22.5M) to support pipeline advancement and pre-commercial activities.
Analysis · IDYA · Life Sciences
IDEAYA's Q2 update reinforces its transition toward a commercial-stage oncology company. The darovasertib NDA submission is underway under the FDA's real-time oncology review program, with completion expected in H2 2026 — a major regulatory milestone. The company also announced multiple upcoming data presentations at ESMO, including updated results from the IDE849 DLL3 ADC program and the darovasertib neoadjuvant trial, which could expand the drug's market opportunity. With $1.24 billion in cash and runway into 2030, IDEAYA is well-funded to execute its pipeline, though the $112.5 million quarterly net loss highlights the high cost of its broad clinical development strategy.
At the time of this filing, IDYA was trading at $35.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $22.09 to $40.58. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.